News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Qu Biologics Granted Broad New Zealand Patent Involving Immunotherapies Derived From Viruses For Treating A Range Of Cancers


6/5/2014 10:20:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Vancouver, British Columbia- June 4, 2014 - Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced it has been granted its second broad New Zealand patent.

Qu Biologics has been issued New Zealand Patent No.601232. The granted patent involves using components of viruses to stimulate an immune response to treat a range of cancers.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "This important patent broadens our patent scope to include the use of inactivated viral components for the treatment of cancer." Dr. Gunn added, "SSIs, derived from inactivated bacterial and viral components, activate an innate immune response in the specific organ or tissue commonly infected by the pathogen. Since innate immune system defect or deficiency plays an important underlying role in cancer or other immune-related diseases, this site-directed immunostimulation represents a promising new approach to engaging the body's own immune response for the treatment of these important diseases."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are derived from inactivated bacteria or viruses aimed at stimulating the body's immune system against cancer and immune-related disease. The company's SSI platform represents a promising new approach to the treatment of cancer and immune-related disease by addressing the underlying immunological factors. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.

Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics' forward-looking statements due to the risks and uncertainties inherent in Qu Biologics' business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES